Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
Namikawa K, Ito T, Yoshikawa S, Yoshino K, Kiniwa Y, Ohe S, Isei T, Takenouchi T, Kato H, Mizuhashi S, Fukushima S, Yamamoto Y, Inozume T, Fujisawa Y, Yamasaki O, Nakamura Y, Asai J, Maekawa T, Funakoshi T, Matsushita S, Nakano E, Oashi K, Kato J, Uhara H, Miyagawa T, Uchi H, Hatta N, Tsutsui K, Maeda T, Matsuya T, Yanagisawa H, Muto I, Okumura M, Ogata D, Yamazaki N. Namikawa K, et al. Among authors: muto i. Cancer Med. 2023 Sep;12(17):17967-17980. doi: 10.1002/cam4.6438. Epub 2023 Aug 16. Cancer Med. 2023. PMID: 37584204 Free PMC article.
Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases.
Fujisawa Y, Ito T, Kato H, Irie H, Kaji T, Maekawa T, Asai J, Yamamoto Y, Fujimura T, Nakai Y, Yasuda M, Matsuyama K, Muto I, Matsushita S, Uchi H, Nakamura Y, Uehara J, Yoshino K. Fujisawa Y, et al. Among authors: muto i. Eur J Cancer. 2021 Mar;145:210-220. doi: 10.1016/j.ejca.2020.12.021. Epub 2021 Jan 24. Eur J Cancer. 2021. PMID: 33503528
Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance.
Hamada T, Morita A, Suga H, Boki H, Fujimura T, Hirai Y, Shimauchi T, Tateishi C, Kiyohara E, Muto I, Nakajima H, Abe R, Fujii K, Nishigori C, Nakano E, Yonekura K, Funakoshi T, Amano M, Miyagaki T, Makita N, Manaka K, Shimoyama Y, Sugaya M. Hamada T, et al. Among authors: muto i. J Dermatol. 2022 Feb;49(2):253-262. doi: 10.1111/1346-8138.16201. Epub 2021 Oct 18. J Dermatol. 2022. PMID: 34658060
Efficacy of Nivolumab and Ipilimumab Combined Therapy as a First-Line Therapy for Patients with Advanced Melanoma and the Urgent Need for an Effective Second-Line Therapy for Patients with Wild-Type BRAF in Japan: A Single Center Retrospective Study.
Muto I, Koga H, Doi R, Katayama E, Nakama K, Nakama T. Muto I, et al. Kurume Med J. 2023 Nov 30;69(1.2):75-80. doi: 10.2739/kurumemedj.MS6912008. Epub 2023 Oct 3. Kurume Med J. 2023. PMID: 37793888 Free article.
Recent treatment and prognosis in 643 patients with extramammary Paget's disease.
Hatta N, Ogata D, Asai J, Maekawa T, Ito T, Takenouchi T, Kiniwa Y, Miyashita A, Miyagawa T, Muto I, Yamamoto Y, Nagano T, Kiyohara Y, Nakano E, Ohe S, Yamaguchi B, Fukuyama M, Matsuya T, Tsutsumida A, Namikawa K, Yamazaki N. Hatta N, et al. Among authors: muto i. Exp Dermatol. 2024 Feb;33(2):e15030. doi: 10.1111/exd.15030. Exp Dermatol. 2024. PMID: 38375900
Loss of heterozygosity in a case of glomuvenous malformations.
Ohata C, Matsuda M, Hamada T, Shintani T, Muto I, Nagata H, Furumura M, Nakama T. Ohata C, et al. Among authors: muto i. J Dermatol. 2015 Jun;42(6):646-7. doi: 10.1111/1346-8138.12849. Epub 2015 Mar 21. J Dermatol. 2015. PMID: 25809388 No abstract available.
Cutaneous Histiocytic Sarcoma With Cellular Cannibalism.
Nanri A, Katayama E, Imamura T, Muto I, Saruta H, Akiba J, Ohshima K, Nakama T, Ohata C. Nanri A, et al. Among authors: muto i. Am J Dermatopathol. 2020 Apr;42(4):286-291. doi: 10.1097/DAD.0000000000001525. Am J Dermatopathol. 2020. PMID: 31567137
44 results